Genzyme shareholders may miss out on first CVR payment
This article was originally published in Scrip
Executive Summary
Former Genzyme shareholders are likely to miss out on the first anticipated contingent value right (CVR) milestone, Sanofi claims, owing to continuing manufacturing delays with Fabrazyme, the Fabry disease treatment.